Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Continues to outpace industry - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 18, 2000

    Sun Pharma: Continues to outpace industry

    Sun Pharma continued its good run, outpacing the overall pharmaceutical industry. While the topline shot up by over 28%, the bottomline grew by a mind boggling 55%.

    During the quarter the amalgamated the operations of Gujarat Lyka by allotting 0.47 m shares in the ratio of 1 share for every 21.33 shares of Gujarat Lyka. If one were to account for the fact that the sales figures for corresponding quarter in the previous year, did not include domestic bulk drug sales of Rs. 61.3 m of Gujarat Lyka, the topline growth comes to around 21.6%, which is still very creditable. The earnings also include the profit of Sun Pharmaceutical Exports, a 99.28% subsidiary of the company which is proposed to be merged with the company with effect from April 2000.

    (Rs m) 1QFY00 1QFY01 Change
    Sales 1,029 1,327 28.9%
    Other Income 4 5 32.4%
    Expenditure 782 967 23.6%
    Operating Profit (EBDIT) 247 360 45.5%
    Operating Profit Margin (%) 24.0% 27.1%  
    Interest (net) 7 (3)  
    Depreciation 27 38 38.9%
    Profit before Tax 217 330 52.0%
    Other Adjustments      
    Tax 17 20 16.0%
    Profit after Tax/(Loss) 200 311 55.1%
    Net profit margin (%) 19.5% 23.4%  
    No. of Shares (m) (eoy) 15.4 46.7  
    Diluted no. of shares (m) 46.7 46.7  
    Diluted Earnings per share* 17.1 26.6  

    Coming to the operations themselves the company is currently ranked 5th by retail prescription sales, up from 10th position last year (ORG Retail Chemist Audit, May 2000 & 1999) . Six of the company's speciality brands feature in the top-selling list of 300 pharma brands in the domestic market.

    During the quarter the company launched seven new products key among these were the Cox 2 inhibitor for the treatment of arthritis, Rofact (rofecoxib), the type 2 oral antidiabetic Glypride (glimiperide), Nodict (naltrexone) for use in drug abuse treatments, the allergy treatment Fexotrol (fexofenadine). Milmet's range was enhanced with the addition of Azelast eyedrops (azelastine), and Ketorid eye drops (ketotifen).

    The management has made a statement that their strategy of focus on niche specialty areas would continue in the near future too and they are confident of maintaining double the industry growth rate for the year.

    The stock quotes at Rs 595, which discounts the annualised earnings by 21.4 times.



    Equitymaster requests your view! Post a comment on "Sun Pharma: Continues to outpace industry". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts